The domestic biotech industry has grown further to post revenues of Rs 10,273 crore ($2.56 billion) in fiscal 2007-08.
The biopharma industry in India is coming of age now and the next five years will be a very interesting period for the Indian biotechnology industry. While bioservices will continue to attract significant interest, and biogenerics exports to the regulated markets are likely to produce a quantum leap in company earnings, there is a growing club of companies in India that are developing novel biotechnology-based pharmaceutical products.
The top three — Serum, Biocon and Panacea — are in the biopharma space and retain their 2007 positions. They account for 25 per cent of the total revenue.
Biotech is more promising.
ReplyDeleteThe domestic biotech industry has grown further to post revenues of Rs 10,273 crore ($2.56 billion) in fiscal 2007-08.
The biopharma industry in India is coming of age now and the next five years will be a very interesting period for the Indian biotechnology industry. While bioservices will continue to attract significant interest, and biogenerics exports to the regulated markets are likely to produce a quantum leap in company earnings, there is a growing club of companies in India that are developing novel biotechnology-based pharmaceutical products.
The top three — Serum, Biocon and Panacea — are in the biopharma space and retain their 2007 positions. They account for 25 per cent of the total revenue.